Careful Selection
We like healthcare, curing or improving diseases in all areas, mainly with high medical need or fewest options. We like AI driven transformation in all categories in healthcare including services
However, we are also 100% open to other sectors and industries. As “value seekers” we build on new trends, breakthroughs, better products or services, ideally already AI driven, or soon
Simplicity
& Selection
We have built companies from early, “ingredients and diamonds only” to where they are today. We added financial considerations, skills, some management, ideas, AI and customer insights -hence, we follow value enhancing strategies (EBITA, EV). Nothing else.
We nurture, keep it simple, execute and coach, track (and they us) with same tools business wise as for our EDC investing financial decisions. This unity at its core represents EDCs, ethics driven companies for us and our investors.
Capital
First
Ethics driven (EDCs) has many aspects and means that capital donors must come “first” in good times and on rainy days, too.
Our investors carry the risk of success and failure – while management wants and needs to deliver and can always act first.
EDC also means we provide good transparency, focus and execution – while we all work to common goals – as a united team towards our joint successes.
Ethics
& Values
Success depends on many factors – product, market, team – and attitude, competence, team work, social skills, stamina, courage, perseverance, coolness, careful risk taking – and getting things done swiftly.
Ethics, social values (Aristoteles, Immanuel Kant) and honesty form the basis of our actions, behaviour, deeds, decisions – and rewards in the end
About us
We are a team of around 37 biopharma commercial leaders, R&D, CRO & regulatory (Parexel), AI & IT (AstraZeneca), finance (Harvard, Oxford University, Kellogg EMBAs) and law / IP specialists (Switzerland, EU27, USA, Japan) with mostly 20 years of experience of working together successfully in the best and most rewarding places of our careers. It creates “glue” and trust – a lot of trust and appreciation for each others’ skills and personalities, too
We come from different backgrounds, predominantly from business, biotechnology and science, medicine, IT and machine learning, engineering, data analysis, immunology and a lot of oncology and severe diseases. Life threatening or shortening, all of them. We added solid business, finance and leadership skills (Harvard, Kellogg, Stanford, St. Gallen, Oxford University), latest gen. AI and coding, now agentic (Oxford, MIT, Stanford) and legal skills for IP and patents (Mannheim, St. Gallen, Hagen, Insead, New York). We govern our portfolio in a lean and smart way and provide all aspects of PE and cashflow driven finance and supervision (Harvard, USA, Oxford, Kellogg Northwestern, St. Gallen). We operate and grow based on a new, purely ethics driven, EDC model and lead with clarity, transparency, financial focus, capital first leadership, effective supervision and solid coaching to maximise efforts for patients in need and our investments (few companies, 2-4 per year, investment cycles of 3-5 years, EBITA, EV of 4-8 x or more). We roll over or do longer term MBOs, too, IPOs, all limited to 33% debt to equity ratio for commercial or partnerships).
Few things we’re really good at
We are good at combining break through technologies in break through areas to transform sectors. We like an optimal number of 2 to 3 break through technologies combined in a smart, AI driven way. This makes us unique, and our investments valuable and transformational.
Secondly, we are good at lifting valuations of companies with a business, R&D and financial, EBITA and EV, AI driven markets’ and customers’ approach. We do the same on costs for better focus and execution – and faster value creation. We go long on key drivers of value and short on risks and nice to haves. We like it simple, smart and lean. We hate complexity
We manage from a valuation driven (EV) investor’s perspective towards success (EDC). We are “free cashflow enthusiasts” in the end (EBITA, EV). We run all numbers again and again. We tend to leave upsides in valuations in every line – to make sure our investments are truly in break through areas and have space to deliver nicely. Otherwise, we do not invest.
For tracking, we create improved and gen. and agentic AI driven “business plans” and solid, free cashflow driven workbooks (EBITA). We model expected “value paths” of enterprise value (EV) and EBITA over 10 to 15 years. It also serves as our “tracker” and “northstar” of EV, EBITA, and guides our DCF decision making over time. We use a very small team for that (EQ Swiss EDC). PE and cashflow principles form our “northstar” on valuation (EV) and performance (6 monthly) in our companies
We only operate EDCs as the “how” differentiates our “what”. Ethics matter and we like and apply ethical standards everywhere (Aristoteles, Kant). This is what we are and how we are all built. We watch negative human emotions carefully. Resentment, envy, greed we watch the most as these are the three strongest. We apply this thinking from selection to all elements of delivery of our companies (EDCs)
We also put investors front and center (EDC). They carry the risk. We might offer several timepoints (2-3) to increase or reduce their stakes after 3-4 years. We include individual wishes and situations including taxation. We are mainly equity financed and might go up to a maximum debt to equity ratio of 33% only, which we do not like, before commercialisation or major exits (IPO, pre IPOs). Loyalty and stability come first while flexibility creates value. These not yet leveraged company P&Ls also carries this value passively for any future partner, so the value will be captured while we do not carry too many risks before
In our companies, we assure strong CEOs and teams, experienced and practical leaders, conduct financial reviews and provide updates to investors (6 monthly or for material information). We support with advisors and experts in specific fields and drive value creation together (EV, EBITA) following our “value path” of above. If we do better, faster, we are happy
On board composition, we love operational ex CEOs and C-suites with hands on drive and very warm personalities. This is the best complement to our management teams for performance. Gender and background neutral, they embrace diversity and add relevant, new perspectives but do not dominate. They have their egos under control, too. We are all humble, try to be focused, try to have fun and apply a sense of humour. This give energy and execution. Focus is always key. We love breakthroughs while executing with ethical standards fast and deeply for the benefit of all patients, clients and ourselves
Business Excellence
We love to create simple thus not trivial, break through business plans.
Financial Excellence
Optimising ROI of invested capital and reducing risks in all aspects is our DNA.
Execution & Culture
“When the strategy is clear, execution becomes the new strategy.” Peter Drucker, 1965
Combine technologies & build the 1st global, purely (IO) cancer biopharma company in animal health in Switzerland
As an example, we have taken a deep breath and analysis into a technology in modern cancer therapy in humans and developed an AI driven, low-cost clinical approach to markets worldwide for horses, camels, dogs and even cats later on
The process has led to an AI driven, phase II/III clinical trial programme for EMA and FDA, MEA markets and the attraction of leading equine centers worldwide through personal networks.
We were also invited to open the company presentations in a major Life Sciences CEO Investors’ Conference in early 2025 – positive feedback from all three global regions. (incl. NA, APAC)
Leading Healthcare Commercial Company with products, patient centricity & patient services – with leading omni-channel & AI inclusion
Based on an experienced team from the 1st multi channel, big pharma company, we integrated AI selection and services to increase product usage by superior patient experiences. Both for launches and established, mature brands (data proven)
The company is “good to go” and to be internationally rolled out. We work with our first clients to be fully aligned for their long-term successes and plans
We like to hear from you:
We are good at putting breakthrough technologies, smart and ethical capital and internal AI technologies together, with strong management, boards and independent advisors. We are always open to discuss new opportunities in transformative sectors
breakthrough technologies, life saving or prolonging
We love to hear from you in case you have a transformative or break through technology and want to build further with us, given same values and ethics (EDC)
smart and ethical ESG investments, impact & high returns investors (ESG)
We love to hear from you in case you want to invest in well set up, AI enhanced, risk mitigated, solid businesses, enterprises., given same values and ethics (EDC)
complementary skills, expert services, talent
We love to hear from you in case you want to work with us on precisely defined, set up, risk mitigated, AI & solid business cases, enterprises, given values and ethics fit (EDC) and simplicity (incl. AI)
New and AI driven
service providers
We love to hear from you in case you want to work with us on well set up, risk mitigated, AI & solid businesses, enterprises., given same values and ethics (EDC)
New and AI driven
product builders
We love to hear from you in case you want to work with us on well set up, risk mitigated, AI & solid businesses, enterprises., given same values and ethics (EDC)
New, AI focused & AI interested investors
We love to hear from you in case you want to work with us on well set up, risk mitigated, AI & solid businesses, enterprises., given same values and ethics (EDC)
Our core team
We are a focused team and can count on 15-30 trusted, ethical, experienced “hands on” experts for insights, personal and professional advise, solid functional and risk assessments, for financial evaluations and trust their financial judgment
We can count on their honesty, loyalt and companionship, too
Pipeline of few projects
We have several new projects under assessment in our pipelines that are exciting to us for their value increase & low risks profiles, for being scalable, truly global and financially striking. They ought to be AI integrated products or services – all with breakthrough prospects and operating in fairly stable, healthy and simple way, and in leading, fast growing sectors
Our opportunities are ROI, IRR, X-factors, and multiples driven companies mostly. We add latest AI and ethics and values (EDCs) for their successful build up and a solid team & oversight to help scale operations – IF achievable in a simple way.
Our Clients
Testimonials
The following customers share thoughts and feelings working with us on from various roles or perspectives:
“I have seen the results of the IO product and the presentation at that investor conference. I was impressed how far they could go in just one year – and they go for global launch, exit or mid-term global profitability.”
Former colleague, pharmaceuticals
“Wonderful to see the “dream – team” in Multi Channel of AZ and drug development coming together and building their “model” into an AI driven world. McKinsey and BCG all copied from them, no-one cracked the “AI nut”. What a great solution for many patients and big manufacturers, in breakthrough medical areas, too.
Former colleague, biotech
“I am amazed how open their thinking is with AI and their AI capabilities – from leading gen AI to agent based solutions now. They even embraced a boat and premium car company and driving success, learning from their end customers, to go into longevity. Smart. They bring it to life everywhere with little efforts in Europe and Switzerland”
EMEA head of IT, informatics
Contact us